Biotech & Pharma Stocks - France

"Investing in biotech is an art that requires fluency in both business and science, as well as sophisticated translational skills to connect the two worlds." EcoR1 Capital

12/01/2018 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

05/01/2018 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

29/12/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

24/11/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

23/11/2017 Innate Pharma 5.28(c) -40.07% Volume 6 570 704

22/11/2017 Innate Pharma provides an update on Lirilumab: "The combination of nivolumab plus lirilumab in an extended population of patients with squamous cell carcinoma of the head and neck (SCCHN) did not provide clear evidence of benefit to patients or an obvious development path"

17/11/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

16/10/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

15/09/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

08/09/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

28/07/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

30/06/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

23/06/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

22/06/2017 AB SCIENCE Presents Supportive Data from its Phase 3 Study in Severe SystemicMastocytosis at the 22nd Congress of the European Hematology Association (EHA)

09/06/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

02/06/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Juin 2, 2017 Innate Pharma renforce son portefeuille d’anticorps propriétaires avec l’acquisition de l’anti-C5aR, un anticorps au stade clinique, auprès de Novo Nordisk A/S - Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody,from novo Nordisk A/S

26/05/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

23/05/2017 ONXEO annonce la 10ème recommandation positive du DSMB pour la poursuite de son essai de Phase III de Livatag®, ReLive, dans le cancer primitif du foie - ONXEO Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

ONXEO 4.25 (c) +29.97% Volume 4 624 149 Variation 5 days +40.26%

19/05/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

AB SCIENCE trumpets phase 3 ALS data, but investors seem unmoved FierceBiotech by Phil Taylor

AB SCIENCE - L'Agence européenne confirme son avis négatif sur le masitinib (traitement de la mastocytose indolente systémique) Reuters Variation 1 mois -26.56%

12/05/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

12/05/2017 AB SCIENCE announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice (GCP) standards. AB Science corrected these deficiencies and an audit plan confirming the GCP compliance will be performed in the coming months. ANSM accepted the principle of restarting the clinical studies on the basis on the findings of this independent audit.

11/05/2017 FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure® Variation 1 month +35.21%

09/05/2017 "AB Science Seeks to Shed Skepticism With ALS Drug Data Reveal" TheStreet Adam Feuerstein

"On May 18, the doctors who conducted the clinical trial for AB Science will present the masitinib data at an ALS research meeting in Slovenia."

05/05/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Day-2 French Presidential Election Second Round

May 02, 2017 Variation 5 days +19.13% CELYAD grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents - "Celyad will not be involved in the development of Novartis’ CAR-T cells. Celyad will continue to focus on the development of its CAR-T pipeline, including its allogeneic NKR-2 T-cell immunotherapy in the EU and US territories and in collaboration with Ono Pharmaceuticals, its partner in Japan, Taiwan and Korea."

04/05/2017 Variation 5 jours +17.16% POXEL annonce des premiers résultats positifs pour l’étude de Phase 2b au Japon sur l’Imeglimine dans le traitement du diabète de type 2 - POXEL Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes. "The strong efficacy of Imeglimin observed in this study suggests that its innovative mechanism of action may play an important role in the treatment of type 2 diabetes and could be particularly well-suited for Japanese patients,” said Pascale Fouqueray, MD, PhD, Executive Vice President, Early Development & Translational Medicine of Poxel. “Imeglimin has been successfully studied in over 1,200 subjects and has shown a differentiated product profile combined with favorable safety, and we believe that it has the potential to address the large and growing needs of the type 2 diabetes market.”

21/04/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Day-2 French Presidential Election First Round

BIOMERIEUX 160.50 (c) (13/04) vs 173.35 (c) (21/04) Δ +8.00% Forte dynamique commerciale au 1er trimestre 2017 avec une progression de l’activité de +13,7 %, à taux de change et périmètre constants : 568 millions d’euros de chiffre d’affaires, +16,3 %, à données publiées, Ventes d’équipements en nette accélération - Strong sales dynamic in first-quarter 2017, with sales up 13.7% at constant exchange rates and scope of consolidation: €568 million in sales, Up 16.3% as reported, Equipment sales up sharply

ERYTECH PHARMA 25.73 (c) (13/04) vs 23.99 (c) (21/04) Δ -6.76% POXEL 5.53 (c) (13/04) vs 5.10 (c) (21/04) Δ -7.77%

13/04/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

07/04/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

(04/04/2017) ERYTECH annonce le lancement dans les pays nordiques d’une étude de Phase 2 initiée par des chercheurs avec eryaspase (GRASPA®) dans la LAL - ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL

31/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

ERYTECH PHARMA Variation 5 days +12.40%

Transgene présentera des données d’immunologie précliniques très prometteuses sur sa nouvelle génération de virus oncolytiques armés au congrès annuel de l’AACR à Washington DC (USA) - Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC

Onxeo présentera des données scientifiques sur ses 3 actifs clés en oncologie lors du congrès annuel de l’ACCR : Etudes précliniques avec AsiDNA™, Livatag® et Beleodaq® - Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting: Preclinical studies of AsiDNA™, Livatag® and Beleodaq®

27/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

ERYTECH annonce des résultats positifs dans son étude de phase 2b avec eryaspase pour le traitement du cancer métastatique du pancréas - ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer

“Pancreatic adenocarcinoma is a dismal disease with poor survival outcome,” commented Iman El-Hariry, MD, PhD, Chief Medical Officer of ERYTECH. “We believe this is the first Phase 2b study of an asparaginase product in pancreatic adenocarcinoma, yet it demonstrated a significant 43% reduction in risk of death in a very difficult-to-treat disease with few treatment options. The study had well balanced demographic and baseline patient characteristics. The improvement in OS and PFS was consistent across subgroups. The adverse events observed in this study were consistent with the known safety profile of eryaspase. We would like to thank all of our participating clinical sites for their hard work and commitment to the study.”

24/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

NANOBIOTIX Variation 5 days +4.48%

NANOBIOTIX : LE COMITE D’EXPERTS INDEPENDANTS RECOMMANDE LA POURSUITE DE L’ESSAI DE PHASE II/III EN COURS AVEC NBTXR3 DANS LE SARCOME DES TISSUS MOUS - NANOBIOTIX: THE INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS THE CONTINUATION OF THE ONGOING PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA

Cerenis Therapeutics annonce la présentation de l’étude de Phase II CARAT avec CER-001, à la Conférence 2017 de l’American College of Cardiology (ACC). Non atteinte du critère principal, la régression de la plaque d’athérome chez des patients ayant subi un Syndrome Coronarien Aigu (SCA) - Cerenis Therapeutics announces that CARAT Phase 2 Study data on CER-001 have been presented at ACC annual meeting 2017. Primary endpoint, regression of coronary plaque in ACS, not met. Safety profile of CER-001 is reinforced

20/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)20/03/2017 - Primary analysis is a success and confirms interim analysis

AB Science announces that Frontiers in Aging Neuroscience publishes a comprehensive review on the future potential of masitinib in amyotrophic lateral sclerosis (ALS) 07/03/2017 - This article reviews over 50 advanced-stage clinical trials in 24 candidate drugs conducted over the last 20 years

Cerenis Therapeutics annonce la présentation de l’étude de Phase II CARAT avec CER-001, à la Conférence 2017 de l’American College of Cardiology (ACC). Non atteinte du critère principal, la régression de la plaque d’athérome chez des patients ayant subi un Syndrome Coronarien Aigu (SCA) - Cerenis Therapeutics announces that CARAT Phase 2 Study data on CER-001 have been presented at ACC annual meeting 2017. Primary endpoint, regression of coronary plaque in ACS, not met

17/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

GENFIT 1 month +54.88% Capitalization 1 023.82 MEUR

10/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

CERENIS Variation 5 jours -2.35%, 1 mois -72.67% : JP Morgan AM est sorti du capital - Alta California Management Partners IV s'allège au capital - Sofinnova Partners s'allège au capital (Source CF)

GENFIT Variation sur 5 jours +2.89% 1 mois +35.72%

03/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Genfit bondit, un possible rachat par Novartis évoqué (Reuters) - 02/03/17 GENFIT 27.60(c) +29.64% Volume 2 763 561

Cerenis Therapeutics annonce les résultats de l’étude de Phase II CARAT. Pas de différence statistique observée entre le traitement et le placebo - Cerenis Therapeutics Announces Top line Results of CARAT Phase II Study. No statistical difference observed between CER-001 and placebo - 02/03/17 CERENIS 1.70(c) -78.06% Volume 14 327 726 - 03/03/17 2.05 (c) +20.59% Volume 6 183 159

01/03/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

24/02/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

17/02/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

10/02/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

09/02/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

POXEL's stock falls after analyst downgrade (Socité Générale), price target cut (4.5 €) Variation 5 days -17.42%

SANOFI Variation 5 days +6.04% - Progression du Chiffre d’Affaires et du BNPA des Activités en 2016 à TCC - Sanofi Delivers 2016 Sales and Business EPS Growth at CER

ADOCIA Variation 1 month -59.15% Adocia annonce la décision d’Eli Lilly de mettre fin à la collaboration sur BioChaperone Lispro - Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro

07/02/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

La FDA autorise l'entrée en développement clinique d'UCART123, le candidat médicament CAR-T allogénique « sur étagère » de Cellectis ciblant des tumeurs hématologiques (LAM et LpDC) - FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.

06/02/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Innate Pharma annonce les résultats principaux de l’étude EffiKIR évaluant l’efficacité de lirilumab en monothérapie chez des patients âgés atteints de leucémie aigüe myéloïde - L’étude n’a pas atteint le critère primaire d’efficacité - Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia - The study did not meet the primary efficacy endpoint

03/02/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

31/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

30/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

AB Science émet 520.000 actions nouvelles représentant 1,35% de son capital (12/01/2017) - AB Science launches a share capital increase issuing 520.000 new shares (01/12/2017)

27/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Variation 1 mois -52.82% Adocia annonce la décision d’Eli Lilly de mettre fin à la collaboration sur BioChaperone Lispro - Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro

« We are extremely disappointed and surprised by Lilly’s decision to terminate the collaboration on our product which has demonstrated significant improvement in terms of performance vs Humalog® across 6 clinical studies. Based upon this stage of development, we are convinced that BC Lispro can improve the lives of people with diabetes and Adocia will continue to prepare launch of phase 3 clinical trials while looking for a new partner. » said Gérard Soula, Chairman and CEO

25/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

ADOCIA: Rebound +12.43% Volume 242 009 (01/24/2017 -11.92% Volume 274 819)

-16.47%  Volume 371 913 TXCELL Launches a Capital Increase of around 11 Million Euros with Shareholders' Preferential Subscription Rights

23/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

41.10 -6.80% Variation Jan 1st -32.62%  Adocia annonce l’évolution de son modèle économique afin d’augmenter la valeur de ses projets - ADOCIA announces the transformation of its business model to increase the value of its projects

20/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

AB SCIENCE Variation 3 days -8.07% - CELLECTIS Variation 5 days -3.70% - CELYAD Variation 2 days -7.72% Profit Taking

ADOCIA Variation sur 5 jours -12.95% Adocia announces the transformation of its business model to increase the value of its projects - With its experience on BioChaperone® Lispro, Adocia intends to develop its projects further, at least to Phase 3. - Three new projects targeting major markets are expected to enter clinical trials this year - Adocia’s portfolio of projects is one of the most differentiated in the industry with a particular focus on improving treatment for people with type 1 diabetes.

17/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

16/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

13/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

CELYAD 19.540 (c) +5.05% Volume 30 140

"Analyst says Celyad takes lead in CAR-T for solid tumors" FierceBiotech

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium (11/01/2017)

12/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Biotechs are down after Trump's comments

11/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

06/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

05/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

NEOVACS signe un partenariat avec le SUNNYBROOK INSTITUTE de Toronto, au Canada pour le développement préclinique du VEGF Kinoïde dans le cancer colorectal et le cancer des ovaires - NEOVACS to collaborate with the SUNNYBROOK RESEARCH INSTITUTE for preclinical development of VEGF Kinoid to treat colorectal cancer and ovarian cancer

03/01/2017 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

CELLECTIS a soumis une demande d’essais cliniques pour UCART123 un produit allogénique fondé sur des cellules CART ingéniérées ciblant des tumeurs hématologiques (LAM et LpDC) - CELLECTIS Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN

29/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

28/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

OSE Immunotherapeutics +21.36%

OSE Immunotherapeutics signe une option de licence avec Servier pour le développement et la commercialisation du produit Effi-7 - OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7

ADOCIA Variation 1 week +12.24%

December 16, 2016 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with type 1 diabetes - Adocia et Lilly annoncent le succès d’une étude évaluant BioChaperone Lispro, administrée par pompe à insuline, chez des personnes avec un diabète de type 1

19/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

INNATE PHARMA annonce des évolutions dans son management et sa gouvernance pour accompagner les prochaines étapes de son développement - INNATE PHARMA announces key leadership and corporate governance changes to support next stage of development

Mondher Mahjoubi, MD, appointed Chairman of Innate Pharma’s Executive Board

Hervé Brailly, PhD, co-founder and CEO from Company inception, appointed Chairman of Supervisory Board

Governance changes aim at driving the Company strategy towards late-stage development

16/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

15/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

09/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

07/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

PROFIT TAKINGS: BONE THERAPEUTICS, CELLECTIS, CELYAD, GENFIT, INNATE PHARMA, & TXCELL

06/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Variation 5 days CELYAD +12.01% ERYTECH PHARMA +14.91% GENFIT +22.42%

CELYAD’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016 during a poster session, taking place on December 3-6, 2016, in San Diego, CA

ERYTECH Presents New Data on GRASPA’s Mechanism of Action at ASH Annual Meeting

Le laboratoire français GENFIT étudie actuellement différentes options stratégiques parmi lesquelles celles d'une vente, écrit lundi Bloomberg en citant plusieurs personnes proches du dossier (Reuters 5 décembre 2016)

05/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Variation 5 days AB SCIENCE +19.98% CELYAD +0.05% ERYTECH PHARMA +10.77% GENTICEL +130.77%

02/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

01/12/2016 AB SCIENCE will present phase 3 results in severe systemic mastocytosis at the Journées Dermatologiques de Paris. (December 6 - 10, 2016, Paris, France) - Important step in the rapid treatment of patients in case of masitinib marketing authorization. Based on these results, AB Science filed for registration to European Medicines Agency (EMA) in April 2016.

CELYAD’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016 during a poster session, taking place on December 3-6, 2016, in San Diego, CA.

BIOPHYTIS: Profit Taking -3.60%

TXCELL - Speculative behavior among investors: 01/12 +22.22% followed by 02/12 -14.55%

01/12/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

TxCell aligne sa structure opérationnelle avec sa réorientation stratégique - TxCell completes aligning operations with strategic refocus (11/29/2016)

30/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

BIOPHYTIS annonce le succès de l’étude clinique SARA-PK dans la sarcopénie - BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile

29/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

QUANTUM GENOMICS : Initiation de couverture par Edison Investment Research : "La prochaine génération de médicaments contre les maladies cardiovasculaires Objectif de cours à 20.51 EUR - "Initiation of coverage by Edison Investment Research: "The next generation of cardiac drugs". Edison raised its price target  to 20.51 EUR.

25/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

ABIVAX 7.61 (c) +8.71% Volume 24 296 Variation 3 months + 89.30%

ABIVAX organise un déjeuner investisseurs avec des leaders d’opinion qui portera sur les nouvelles approches thérapeutiques pour lutter contre le VIH - ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy November 28, 2016 in New York

QUANTUM GENOMICS Une visibilité financière de l’ordre de 18 mois - 18-month financial visibility October 13th, 2016

21/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

ONCODESIGN wins the 4th European Small and Mid-Cap Awards in the "Rising Star" category: ONCODESIGN 15.93 +6.20% trading in Low Volume 19 144

POXEL to Present New Imeglimin Data Demonstrating Beta Cell Function Preservation at the 14th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease - December 1-3, 2016, at the Hilton Universal City Hotel in Los Angeles, California.

18/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

ONCODESIGN : Guidance stratégique 2020 : 40 M€ de chiffre d’affaires et rentabilité positive - 2020 Strategic guidance: €40 million in revenue and profitable

16/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

CELLECTIS Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123

CELLECTIS annonce avoir réalisé avec succès les campagnes de production de son second produit candidat UCART123 selon les Bonnes Pratiques de Fabrication (BPF)

15/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

ERYTECH Announces Withdrawal of Its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission

Withdrawal of European Marketing Authorization Application (MAA) for eryaspase (GRASPA®); additional data requested by the Committee for Human Medicinal Products (CHMP) will take more time to provide than allowed in the CHMP’s approval procedures - Intention to resubmit the MAA mid-2017

INNATE PHARMA: Invest Securities maintient l'achat - Portzamparc toujours acheteur (Source Cercle Finance)

NANOBIOTIX - Profit Taking

14/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

POXEL Joins Organizations Worldwide to Recognize World Diabetes Day

NANOBIOTIX PRESENTS NBTXR3 PRECLINICAL DATA DEMONSTRATING ITS POTENTIAL USAGE AS IN SITU VACCINE FOR CANCER AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING

11/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

A third straight day of gains for Oncology Biotech Stocks

10/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

A second straight day of gains after Trump victory

09/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

"Biotech Stocks Jump as Donald Trump Clinches Presidency in Major Upset" BioSpace

08/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

The Biotech Sector is in a Downward Trend

07/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

Celyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016

04/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

The Biotech Sector is in a Downward Trend

03/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

BONE THERAPEUTICS 8.273 +19.90% Volume 89 459 - Notice of Q3 2016 Results - Results to be announced on 8 November 2016

INNATE PHARMA 11.05 +4.44% Volume 289 312  - CA à neuf mois multiplié par 2.5 - Oddo & Portzamparc restent à l'Achat

Third quarter 2016 report (Press Release - Innate Pharma)

- Cash, cash equivalents and financial assets amounting to €239.6 million

- Continued progress with key clinical trials

- Safety data for lirilumab in combination in Phase I studies presented at the ESMO 2016 Congress:

The combination of lirilumab and nivolumab in a Phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy - Efficacy data for the lirilumab-nivolumab combination in head and neck cancer will be presented at the SITC 2016 annual meeting

- Encouraging preliminary safety and clinical activity results for IPH4102 in a Phase I study presented at the 3WCCL 2016 meeting

02/11/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

The Biotech Sector is in a Downward Trend

28/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

The Biotech Sector is in a Downward Trend

27/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

The Biotech Sector is in a Downward Trend

26/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

The Biotech Sector is in a Downward Trend

25/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

The Biotech Sector is in a Downward Trend

21/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

The Biotech Sector is in a Downward Trend

20/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

19/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

The Biotech Sector is in a Downward Trend

18/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

The Biotech Sector is in a Downward Trend

14/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

13/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

12/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

The Biotech Sector is in a Downward Trend

10/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

07/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

06/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

GENFIT LANCE UNE AUGMENTATION DE CAPITAL PAR PLACEMENT PRIVE - GENFIT LAUNCHES A SHARE CAPITAL INCREASE THROUGH PRIVATE PLACEMENT

04/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

28/09/2016. INNATE PHARMA - Présentation des données de tolérance des essais de phase I de Lirilumab en combinaison avec Nivolumab ou Ipilimumab au congrès de l’ESMO 2016 - Safety data for Lirilumab in combination with Nivolumab or Ipilimumab to be presented at the ESMO 2016 Congress

29/09/2016. INNATE PHARMA - Poursuite de l’essai EffiKIR sans modification après la septième évaluation du comité de revue des données et de la tolérance. Le recrutement des patients dans l’étude s’est achevé en juillet 2014. L’analyse du critère primaire d’efficacité, la survie sans leucémie, est de type « event driven » et pourrait avoir lieu avant la fin 2016. - Seventh data and Safety Monitoring Board Meeting of the EffiKIR trial recommends continuation without modification. Enrolment in the EffiKIR study was completed in July 2014. The analysis on the primary endpoint, leukemia-free survival, is event driven and could occur by the end of 2016.

O28/10/2016. ONCODESIGN - GSK et Oncodesign annoncent la signature d’un accord pour l’acquisition par Oncodesign du centre de recherches de GSK en France - GSK and Oncodesign announce agreement for Oncodesign’s acquisition of GSK’s Research Centre in France

03/10/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE - Twitter: @TradingPharma

30/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

AB SCIENCE : Filing of masitinib in the treatment of amyotrophic lateral sclerosis to the European Medicine Agency (EMA). The review process started on 12 September 2016.    

QUANTUM GENOMICS annonce des résultats positifs pour l’étude clinique de phase IIa de QGC001 dans l’hypertension artérielle (29/09/2016) -  Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

ONXEO : Réussite de l'augmentation de capital (12.5 M euros)  - Successful capital increase

29/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

28/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

27/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

26/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

23/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

22/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE

21/09/2016 - Clôture. MISE À JOUR DU MARCHÉ - MARKET UPDATE 

20/09/2016 - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS 

16/09/2016 - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS

JOURNÉE DES 4 SORCIÈRES - QUADRIPLE WITCHING DAY - SPECULATIVE BIOTECH MARKET

15/09/2016 - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS

VEILLE DE LA JOURNÉE DES 4 SORCIÈRES - EVE OF QUADRIPLE WITCHING DAY - SPECULATIVE BIOTECH MARKET

 

14/09/2016 - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS

13/09/2016  - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS - FRANCE

12/09/2016  - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS - FRANCE

09/09/2016 - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS - FRANCE

Source Boursorama

07/09/2016 - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS - FRANCE

06/09/2016 - Clôture. MARKET UPDATE - BIOTECH & PHARMA STOCKS - FRANCE

Source Boursorama